If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.
We set cookies so you can manage your account and navigate the site, and to remember your cookie preferences so that you don't keep getting this message. To accept cookies, just keep browsing, otherwise use the links on the right to adjust your cookie settings or find out more.
According to a major pooled analysis by the US Food and Drug Adminis-tration (FDA) published last month, the use of long-acting beta-agonists, or LABAs, is associated with a significantly increased incidence of serious asthma-related adverse events, including hospitalizations and death (Pediatrics, 2011; 128: e1147-54)